Sarah Meibusch


|   BAgrSc(Hons), M.P.S, GAICD   |   Location: Brisbane, AU

Sarah is responsible for sourcing life sciences companies and actively shaping their future. She applies her global executional experience and entrepreneurial passion to nurture their success. Her enterprise level leadership experience has been forged over 20 years in a wide spectrum of organisations, including start-up, private companies, ASX and NASDAQ-listed companies, a multi-national pharmaceutical company and university research organisations.

Prior to OneVentures, she was the Asian Business Development lead for Shire Pharmaceuticals (now Takeda), a global specialty pharmaceutical company. Sarah identified technologies and developed collaborations across Japan, Korea, Australia, New Zealand, Singapore and Taiwan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015.

Sarah has held senior management roles at Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics. From 2011-2017 she led the development of the new UQ QAAFI research institute from 32 people to 450 people and a financially profitable position within 5 years. This included leading the negotiation of a complex $70+M staff transfer and research agreement for QAAFI between the University of Queensland and the Queensland Government. In 2012, Sarah spearheaded the IP asset assignment and company wind-up of 20 year $168M Beef Co-operative Research Centre, involving five universities across five state jurisdictions, MLA, CSIRO and Meat and Lamb NZ and pastoral companies. At Progen Pharmaceuticals, Sarah worked collaboratively with the CEO and CFO over several years to secure a total financing of ~$125M via five capital raisings for oncology drug development, and in 2008 led the $22M acquisition of an oncology drug discovery company.

Sarah has a strong understanding of the pharmaceutical, medical device and healthcare industries including key inflexion points, intellectual property, regulatory and reimbursement strategies, business development options and strategic product management. She combines this with the ability to understand scientific information quickly and build credibility with technical experts and industry players. She is passionate about commercialising new technologies, and has the strategic vision and positive energy to deliver under tight timeframes in a team environment.

Sarah is a graduate of the Australian Institute of Company Directors (GAICD) and currently holds directorships with Kira Biotech, QAAFI Advisory Board and Life Sciences Queensland. She holds Bachelor level science qualifications from the University of Queensland and a Masters from Cornell University and has completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.

decor decor decor
decor decor decor decor decor